Longevium plans 730 sqm Bali clinic in 2027 as Dubai longevity model goes abroad

Longevium, a Dubai-based longevity medicine group, plans to open a 730-square-metre outpatient clinic in Bali in 2027, taking a Dubai preventive-care model into an international self-pay market.

The highest-stakes readers are clinic owners, COOs and CFOs. The issue is whether longevity medicine becomes a repeatable outpatient line for UAE providers, or remains a premium wellness product with limited insurer support. Dubai clinics will answer first under the Dubai Health Authority (DHA); Abu Dhabi operators will face the Department of Health Abu Dhabi (DOH); northern emirate providers will deal with the Ministry of Health and Prevention (MOHAP).

What Gulf News reported

Gulf News reported on 17 September 2026 that Longevium will develop the Bali clinic with Nuanu founder Sergey Solonin. The facility is aimed at medical travellers and residents seeking ongoing preventive care. Longevium said patients could start programmes in Dubai and continue overseas, or begin abroad and return to Dubai for follow-up.

The company says it operates three clinics in Dubai and has served more than 30,000 patients. It is also planning a clinic in Abu Dhabi and a research laboratory at Dubai Science Park. Founder Dr Ksenia Butova has positioned the group around preventive medicine, diagnostic testing and digital tracking.

“Longevity medicine is only as good as its data.”
Sergey Shayakhmetov, co-founder of Longevium

The Bali clinic is expected to include diagnostic assessments, digital health modelling, robotic blood collection, hyperbaric oxygen treatment and personalised recovery programmes. Gulf News said regenerative therapies and other emerging treatments would depend on local regulatory approvals.

Why UAE clinics and insurers should care

For UAE providers, the commercial question is narrow: can longevity medicine produce repeat visits without overpromising clinical outcomes? Executive health checks in the UAE give a price floor. Published packages range from AED 700 for a basic executive check at Dr. Sulaiman Al Habib Hospital to AED 25,000-AED 30,000 for executive plans at American Hospital Dubai. Longevity programmes with genomics, advanced imaging, IV therapies or hyperbaric sessions usually sit above routine screening, but clinics should price them from listed components rather than invented bundles.

Insurers are unlikely to treat broad longevity programmes as standard medical necessity without diagnosis codes, clinical indication and prior approval. In Abu Dhabi, Thiqa is managed by Daman for eligible UAE nationals, according to the Thiqa programme. In Dubai, coverage depends on the plan terms, medical necessity and network status. Operators should separate reimbursable consultations, labs and imaging from elective wellness items at the point of sale.

• COOs should check whether each service needs a DHA, DOH or MOHAP facility activity, equipment approval or physician privilege.
• CFOs should model longevity revenue as mostly cash-pay unless payer contracts state otherwise.
• CIOs should treat cross-border records as a consent, cybersecurity and interoperability project.
• Medical directors should document clinical indications for tests and therapies, especially regenerative claims.

The operating test in Dubai

Longevium’s model depends on longitudinal data. That matters in Dubai because NABIDH, DHA’s health information exchange, is designed for exchanging medical records between healthcare providers, according to the NABIDH portal. Any Dubai clinic building a longevity product should confirm whether its electronic medical record can support consent capture, lab feeds, radiology results, prescriptions and audit trails before selling multi-year programmes.

The licensing path is equally important. DHA’s facility licensing service covers new healthcare facilities in Dubai under DHA jurisdiction. Abu Dhabi operators need DOH approval, and northern emirate operators need MOHAP approval. A clinic licensed for family medicine or aesthetics should not assume that hyperbaric oxygen, regenerative medicine, genetic testing or pharmacy dispensing sits within the same activity.

Patients will see a simpler proposition: preventive care with a premium price and digital continuity. That creates a marketing opportunity for Dubai clinics, but it also raises liability. If a patient buys a longevity package after a social media campaign, the consent form, physician note and test rationale need to withstand regulator review.

Pharmacies have a related opportunity in supplements, prescribed medicines and cold-chain products attached to longevity care. They also carry risk if clinics blur retail wellness with regulated therapy. Before adding pharmacy partners to a longevity pathway, operators should verify licences and location coverage through the UAE Open Healthcare Directory for licensed pharmacy providers.